HIV Testing Among Transgender Women and Men - 27 States and Guam, 2014-2015
Overview
Affiliations
Transgender persons are at high risk for human immunodeficiency virus (HIV) infection; in a recent analysis of the results of over nine million CDC funded HIV tests, transgender women* had the highest percentage of confirmed positive results (2.7%) of any gender category (1). Transgender men, particularly those who have sex with cisgender men, are also at high risk for infection (2). HIV testing is critical for detecting and treating persons who are infected and delivering preventive services to those who are uninfected. CDC recommends that persons at high risk for HIV infection be screened for HIV at least annually, although transgender persons are not specified in the current recommendations. CDC analyzed data from the Behavioral Risk Factor Surveillance System (BRFSS) to describe HIV testing among transgender women and men and two cisgender comparison groups in 27 states and Guam. After adjusting for demographic characteristics, transgender women and men had a lower prevalence of ever testing and past year testing for HIV (35.6% and 31.6% ever, and 10.0% and 10.2% past year, respectively) compared with cisgender gay and bisexual men (61.8% ever and 21.6% past year) and instead reported testing at levels comparable to cisgender heterosexual men and women (35.2% ever, and 8.6% past year). This finding suggests that transgender women and men might not be sufficiently reached by current HIV testing measures. Tailoring HIV testing activities to overcome the unique barriers faced by transgender women and men might increase rates of testing among these populations.
Gamarel K, Jennings Mayo-Wilson L, Jadwin-Cakmak L, Reyes L, Monro D, Ubong I Pilot Feasibility Stud. 2024; 10(1):135.
PMID: 39511631 PMC: 11545932. DOI: 10.1186/s40814-024-01558-5.
Infections Following Gender-Affirming Vaginoplasty: A Single-Center Experience.
Sheth R, Bhaskara A, Brown H, Varley C, Streifel A, Maier M Open Forum Infect Dis. 2024; 11(10):ofae526.
PMID: 39411218 PMC: 11474599. DOI: 10.1093/ofid/ofae526.
Zamantakis A, Merle J, Queiroz A, Zapata J, Deskins J, Pachicano A Implement Sci Commun. 2024; 5(1):111.
PMID: 39380128 PMC: 11462864. DOI: 10.1186/s43058-024-00638-0.
Guss C, Pilcher S, Assefa I, Fitzgerald S, Stamoulis C, Woods E Transgend Health. 2024; 9(2):128-135.
PMID: 38585242 PMC: 10998023. DOI: 10.1089/trgh.2021.0163.
Bacterial vaginosis testing gaps for transmasculine patients may exacerbate health disparities.
Thompson H, Rusie L, Schneider J, Mehta S Front Reprod Health. 2024; 6:1344111.
PMID: 38449898 PMC: 10916334. DOI: 10.3389/frph.2024.1344111.